These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12704736)

  • 1. Screening for chromosomal defects.
    Nicolaides KH
    Ultrasound Obstet Gynecol; 2003 Apr; 21(4):313-21. PubMed ID: 12704736
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for Down's syndrome--too many choices?
    Mennuti MT; Driscoll DA
    N Engl J Med; 2003 Oct; 349(15):1471-3. PubMed ID: 14534341
    [No Abstract]   [Full Text] [Related]  

  • 3. [First trimester diagnosis of chromosomal defects].
    Nicolaides KH; Wegrzyn P
    Ginekol Pol; 2005 Jan; 76(1):1-8. PubMed ID: 15844559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
    Nicolaides KH
    Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union?
    Thilaganathan B
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):229-30. PubMed ID: 10341398
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].
    Senat MV; Rozenberg P; Bernard JP; Ville Y
    J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal bone in first-trimester screening for trisomy 21.
    Cicero S; Avgidou K; Rembouskos G; Kagan KO; Nicolaides KH
    Am J Obstet Gynecol; 2006 Jul; 195(1):109-14. PubMed ID: 16813749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
    Spencer K
    Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of nuchal translucency in contemporary obstetric practice.
    Said S; Malone FD
    Clin Obstet Gynecol; 2008 Mar; 51(1):37-47. PubMed ID: 18303498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
    Avgidou K; Papageorghiou A; Bindra R; Spencer K; Nicolaides KH
    Am J Obstet Gynecol; 2005 Jun; 192(6):1761-7. PubMed ID: 15970804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
    Nicolaides KH; Bindra R; Heath V; Cicero S
    J Matern Fetal Neonatal Med; 2002 Jul; 12(1):9-18. PubMed ID: 12422904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trisomy 18 in a fetus with normal NT and abnormal maternal serum biochemistry.
    De Biasio P; Canini S; Prefumo F; Venturini PL
    Prenat Diagn; 2002 Jun; 22(6):492-3. PubMed ID: 12116311
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of maternal smoking on prenatal screening for Down syndrome and trisomy 18 in the first trimester of pregnancy.
    Miron P; Côté YP; Lambert J
    Prenat Diagn; 2008 Mar; 28(3):180-5. PubMed ID: 18264956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester screening: an overview.
    Eiben B; Glaubitz R
    J Histochem Cytochem; 2005 Mar; 53(3):281-3. PubMed ID: 15750002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
    Spencer K; Spencer CE; Power M; Dawson C; Nicolaides KH
    BJOG; 2003 Mar; 110(3):281-6. PubMed ID: 12628268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.